Patrick Machado

October 11, 2026

Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.

October 16, 2026

Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.

October 8, 2026

Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).